Jacobs Levy Equity Management
DCPH

Jacobs Levy Equity Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Jacobs Levy Equity Management’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-471,977
Closed -$7.42M – 1077
2024
Q1 		$7.42M Buy
471,977
+47,936
+11% +$738K 0.03% 357
2023
Q4 		$6.84M Sell
424,041
-283,062
-40% -$3.61M 0.03% 367
2023
Q3 		$8.99M Sell
707,103
-148,172
-17% -$2.04M 0.05% 274
2023
Q2 		$12M Sell
855,275
-22,862
-3% -$327K 0.07% 252
2023
Q1 		$13.6M Sell
878,137
-341,943
-28% -$5.71M 0.08% 242
2022
Q4 		$20M Sell
1,220,080
-91,476
-7% -$1.49M 0.14% 191
2022
Q3 		$24.3M Buy
1,311,556
+112,547
+9% +$1.77M 0.19% 142
2022
Q2 		$15.8M Buy
1,199,009
+948,069
+378% +$10.5M 0.12% 202
2022
Q1 		$2.33M Sell
250,940
-1,077
-0.4% -$9.16K 0.02% 593
2021
Q4 		$2.46M Buy
252,017
+231,382
+1,121% +$4.35M 0.02% 578
2021
Q3 		$701K Sell
20,635
-55,937
-73% -$1.79M ﹤0.01% 815
2021
Q2 		$2.8M Sell
76,572
-35,411
-32% -$1.37M 0.02% 541
2021
Q1 		$5.02M Buy
111,983
+72,947
+187% +$3.4M 0.04% 416
2020
Q4 		$2.23M Buy
+39,036
New +$2.31M 0.02% 557

Other funds holding DCPH

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Jacobs Levy Equity Management's DCPH Position: Q2 2024 in Review

Jacobs Levy Equity Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 471,977 shares — an estimated $7.42M sold.

Jacobs Levy Equity Management first reported a position in DCPH in Q4 2020 and held it in 14 quarters. The position peaked at $24.3M in Q3 2022. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.

  • Jacobs Levy Equity Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 471,977 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $7.42M.
  • Jacobs Levy Equity Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 14 quarters.
  • Jacobs Levy Equity Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $24.3M in Q3 2022.
  • 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2024, filed 14 Aug 2024.